OTIVIO CASE: Uncovering opportunities to improve quality of life for people with MS
PÅ DANSK →
FlowOx is developed by MedTech startup Otivio as a game-changing new treatment for people living with Multiple Sclerosis. Treatment with pulsating, negative pressure therapy has been shown to reduce cramps, pain, and muscle stiffness, which for a significant proportion of pwMS is otherwise debilitating and reduces the quality of life. The treatment is also drug-free and takes place at the patient’s home.
Ipsos Healthcare has designed a multi-methodological study to help Otivio getting closer to the patient group, thus gaining deeper understanding of how the disease affects their lives and how they approach and manage their spasticity symptoms. The study has also mapped how patients relate to FlowOx as a new drug-free form of treatment and their willingness to trial and self-pay the medical device. In conclusion a large treatment potential has been uncovered and Ipsos outlined a number of concrete recommendations for the further go-to-market strategy for the product.
Ipsos has proven to be the research partner that can take us beyond the existing, and extensive, research results on medical side-effect. And help us to understand how different levels of MS-related spasticity affect patients in their daily lives and how to best meet patient’s needs.
- Chief Commercial Officer, Otivio
 | Be in the know!Sign up to Ipsos Insights to get a monthly email with invitations to events and webinars, case stories, POV’s, whitepapers and news. |
Follow us for many more insights:
 |  |  |  |
